MedCity News December 8, 2024
Marissa Plescia

After the FTC filed a lawsuit in September, accusing the three major pharmacy benefit managers of anticompetitive rebating practices related to insulin, the defendants reversed roles and became plaintiffs. In November, they countersued the agency, arguing that its lawsuit is unconstitutional.

CVS Caremark, Express Scripts and Optum Rx are fighting back.

After the FTC filed a lawsuit in September, accusing the three major pharmacy benefit managers of engaging in anticompetitive rebating practices tied to insulin, the defendants have turned plaintiff. In November, they countersued the agency, claiming its lawsuit is unconstitutional.

The move could be a possible delay tactic, as well as a message to the FTC that they will leave no stone unturned in order to defend themselves,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Govt Agencies, Pharma, Pharma / Biotech
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
How has U.S. Spending on Health Care Changed Over Time?
Merck enters $2B licensing deal for weight loss drug
What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices

Share This Article